Prolonged survival of patients with angioimmunoblastic T‐cell lymphoma after high‐dose chemotherapy and autologous stem cell transplantation. The GELTAMO experience
José Rodríguez(The University of Texas MD Anderson Cancer Center), Pascual Fernández(Hospital General Universitario de Alicante Doctor Balmis), M. Gandarillas(Marqués de Valdecilla University Hospital), Alfonso J. Rodríguez‐Morales(Universidad Científica del Sur), M. Bendandi(Clinica Universidad de Navarra), Juan Bergua(Hospital San Pedro de Alcántara), Guillermo Cañigral(Hospital General Universitari de Castelló), José M. Moraleda(Centro Regional de Hemodonación), Anna Sureda(Institut d'Investigació Biomédica de Bellvitge), Josep‐María Ribera(Universitat Autònoma de Barcelona), Carmen Albó(Spanish National Centre for Cardiovascular Research), Ángel León(Hospital Jerez Puerta del Sur), Marı́a Dolores Caballero(Complejo Hospitalario de Salamanca), Eulogio Conde(Marqués de Valdecilla University Hospital), Dolores Carrera(Hospital Universitario Central de Asturias), Reyes Arranz, Antonio Gutiérrez(Hospital Universitario Son Dureta), Jesús Ojanguren(Hospital de Galdakao)
Cited by 60
Related Papers
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
|The Lancet Oncology|2014|1.3k
Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2022|718
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
|New England Journal of Medicine|2023|538